Baseline demographics and clinical characteristics
| Demographics | Total (n=443) | Risankizumab (150 mg) (n=224) | Placebo (n=219) |
| Sex, n (%) | |||
| Female | 224 (55.1) | 124 (55.4) | 120 (54.8) |
| Age (years), mean±SD | 52.9±12.6 | 53.1±12.5 | 52.7±12.6 |
| White race, n (%) | 428 (96.6) | 218 (97.3) | 210 (95.9) |
| Duration of PsA (years), mean±SD | 8.2±8.3 | 8.2±8.2 | 8.2±8.3 |
| Presence of dactylitis (LDI >0), n (%) | 97 (22.0) | 40 (17.9) | 57 (26.3) |
| Presence of enthesitis (LEI >0), n (%) | 305 (68.8) | 147 (65.6) | 158 (72.1) |
| PASI (in patients with BSA ≥3%), mean±SD | 8.0±8.4 | 7.7±6.7 | 8.4±9.9 |
| Tender joint count (68 joints), mean±SD | 22.6±14.4 | 22.8±14.9 | 22.3±13.8 |
| Swollen joint count (66 joints), mean±SD | 13.3±8.9 | 13.0±8.7 | 13.6±9.0 |
| Body surface area—psoriasis ≥3, n (%) | 242 (54.6) | 123 (54.9) | 119 (54.3) |
| Number of prior csDMARDs, n (%) | |||
| 0 | 23 (5.2) | 12 (5.4) | 11 (5.0) |
| 1 | 169 (38.1) | 88 (39.3) | 81 (37.0) |
| 2 | 120 (27.1) | 60 (26.8) | 60 (27.4) |
| >3 | 131 (29.6) | 64 (28.6) | 67 (30.6) |
| Number of prior bDMARDs, n (%) | |||
| 0 | 237 (53.5) | 119 (53.1) | 118 (53.9) |
| ≥1 | 206 (46.5) | 105 (46.9) | 101 (46.1) |
| Number of prior failed bDMARDs, n (%) | |||
| 0 | 269 (60.7) | 137 (61.2) | 132 (60.3) |
| 1 | 136 (30.7) | 72 (32.1) | 64 (29.2) |
| ≥2 | 38 (8.6) | 15 (6.7) | 23 (10.5) |
| Concomitant csDMARD at baseline, n (%) | |||
| Any csDMARD | 270 (60.9) | 141 (62.9) | 129 (58.9) |
| Any MTX | 209 (47.2) | 110 (49.1) | 99 (45.2) |
| MTX alone | 191 (43.1) | 102 (45.5) | 89 (40.6) |
| MTX and other csDMARD | 18 (4.1) | 8 (3.6) | 10 (4.6) |
| csDMARD other than MTX | 61 (13.8) | 31 (13.8) | 30 (13.7) |
| Any sulfasalazine, without MTX | 18 (4.1) | 9 (4.0) | 9 (4.1) |
| Any leflunomide, without MTX | 27 (6.1) | 12 (5.4) | 15 (6.8) |
| Any apremilast, without MTX | 14 (3.2) | 9 (4.0) | 5 (2.3) |
| None | 173 (39.1) | 83 (37.1) | 90 (41.1) |
| BMI in kg/m2, n (%) | |||
| BMI <25 | 76 (17.2) | 38 (17.0) | 38 (17.4) |
| BMI ≥25 to <30 | 136 (30.7) | 68 (30.4) | 68 (31.1) |
| BMI ≥30 | 231 (52.1) | 118 (52.7) | 113 (51.6) |
bDMARD, biologic disease-modifying antirheumatic drug; BMI, body mass index; BSA, body surface area; csDMARD, conventional synthetic disease-modifying antirheumatic drug; LDI, Leeds Dactylitis Index; LEI, Leeds Enthesitis Index; MTX, methotrexate; PASI, Psoriasis Area and Severity Index; PsA, psoriatic arthritis.